At a glance
- Originator Dainippon Sumitomo Pharma
- Class
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Bacterial infections in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 22 Aug 2003 A preclinical study has been added to the Bacterial Infections pharmacodynamics and antimicrobial activity sections